Project Grant F31CA294976

Award Date 12/20/24
Completion Date 7/9/26
Dollars Obligated $88K
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Roanoke, VA 24016, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $210,789 to Texas A&M University System Health Science Center to conduct research aimed at developing a novel antisense therapy targeting the protein DKK-1 for the treatment of osteosarcoma, a common bone cancer. The research will involve characterizing the effects of a canine version of the DKK-1 inhibiting antisense therapy (cDKKMO) on osteosarcoma cell lines and patient-derived...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $275,092 to the University of Wisconsin-Madison to develop an accurate and robust targeting technique to enable transcostal histotripsy treatment of liver tumors. The key objectives are to: 1) quantify the effect of intervening ribs on targeting accuracy through ex-vivo and in-vivo experiments; 2) develop a robust machine learning model to predict targeting offsets; and 3) incorporate...
Oregon State University will receive $500,000 from the National Science Foundation under the Technology, Innovation, and Partnerships program to develop cancer therapeutics for dogs. Specifically, the university will construct and test prototype dual epitope-binding therapeutic antibodies targeting the canine PD-1 protein for the treatment of canine cancers. Researchers will design various single domain antibody configurations and select an optimal construct using recombinant DNA methods and...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to investigate the potential of focused ultrasound (FUS) to enhance chimeric antigen receptor (CAR) T cell therapy for the treatment of medulloblastoma, an aggressive type of pediatric brain cancer. The $244,839 grant, awarded on March 10, 2025, will support a collaborative research effort between the University of Virginia and Children's Research Institute to: Evaluate the...
This Project Grant award of $513,574.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to elucidate the mechanisms and genetic factors underlying osteonecrosis of the jaw (ONJ), a damaging condition that can occur in patients taking anti-resorptive medications. The key products and services to be delivered through this award include: Elucidating the cellular and molecular mechanisms that give...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding of $514,405.00 to Sanford Research to investigate the role of cancer-dependent skeletal genes and pathways in the development and progression of osteosarcoma. The research aims to elucidate the underlying mechanisms of osteosarcoma, a fatal bone tumor primarily affecting children, with a focus on p53 and Notch signaling pathways. The grant supports collaborative work...
This $254,580 National Science Foundation Technology, Innovation, and Partnerships project grant funds the development of artificial intelligence-mediated orthopedic implant design and selection software by Med Dimensions, LLC. The Phase I small business innovation research project aims to create a machine learning system that incorporates bone density screening and 2D to 3D reconstruction to generate anatomically-derived implants and guide implant placement for veterinary use. By integrating...
The Department of the Army Medical Command awarded a $1,750,524 project grant to Dana-Farber Cancer Institute, Inc. for research on treatment options for metastatic osteosarcoma. The grant was awarded on August 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research through July 31, 2025. The Military Medical Research and Development program aims to transform health care for service members and the public through innovative biomedical research....
This R01 project grant, awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is developing a Transcranial Magnetic Resonance (MR) and Ultrasound (US) Guided Histotripsy (TCMR-USGHT) system for the non-invasive treatment of brain tumors. The $543,959 award, with a period of performance from January 15, 2025 to December 31, 2028, supports the...
This Project Grant award, valued at $152,135, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by the University of Texas Health Science Center at Houston (UTHealth) to unravel the role of the RB1 gene in regulating enhancer control and chromatin architecture governing gene transcription in osteosarcoma. The research aims to advance the scientific understanding of osteosarcoma,...

INVESTIGATING TREATMENT STRATEGIES & CLINICAL OUTCOMES OF HISTOTRIPSY FOR COMPLETE ABLATION OF OSTEOSARCOMA - PROJECT SUMMARY OSTEOSARCOMA (OS) IS A COMMON AND DEVASTATING PRIMARY BONE TUMOR AFFECTING BOTH HUMANS AND CANINES. HISTOTRIPSY IS AN EMERGING NON-THERMAL ABLATION MODALITY THAT USES HIGH-PRESSURE FOCUSED ULTRASOUND PULSES TO INDUCE ACOUSTIC CAVITATION AND LIQUIFY TARGET TISSUE WITH HIGH PRECISION. OUR TEAM HAS PIONEERED THE DEVELOPMENT OF HISTOTRIPSY FOR BONE TUMORS WITH CRITICAL EX VIVO AND IN VIVO STUDIES USING EXCISED CANINE OS TUMORS AND PET DOGS WITH SPONTANEOUS OS, RESPECTIVELY. DOGS HAVE AN INCREASED INCIDENCE OF OS WITH HIGH SIMILARITY TO HUMAN OS, ALLOWING THE PET DOG TO SERVE AS A VALUABLE COMPARATIVE ONCOLOGY MODEL. THIS PROPOSAL SEEKS TO FURTHER THE DEVELOPMENT OF HISTOTRIPSY FOR OS TREATMENT BY 1) INVESTIGATING THE TREATMENT PARAMETERS & STRATEGIES NEEDED FOR COMPLETE ABLATION IN EX VIVO CANINE OS, AND 2) TESTING THESE STRATEGIES IN PILOT CLINICAL TRIALS WITH ACUTE AND CHRONIC FOLLOW-UP OF PET DOGS WITH HISTOTRIPSY-TREATED OS. THROUGHOUT THESE EXPERIMENTS, I WILL BE TRAINED IN VITAL SKILLS IN BIO-ENGINEERING AND CLINICAL ONCOLOGY, INCLUDING TRANSMIT-RECEIVE CIRCUITRY (DR. TIM HALL AT UNIVERSITY OF MICHIGAN), HISTOPATHOLOGICAL ANALYSIS OF ABLATION (DR. SHERYL COUTERMARSH-OTT AT VIRGINIA-MARYLAND COLLEGE OF VETERINARY MEDICINE), AND RADIOLOGICAL ASSESSMENT OF ABLATION (DR. TIM ZIEMLEWICZ AT UNIVERSITY OF WISCONSIN). THE RESULTS OF THIS WORK WILL OVERCOME PREVIOUS TECHNICAL & ENGINEERING BARRIERS IN ACHIEVING COMPLETE ABLATION OF BONE TUMORS AND WILL PROVIDE CRUCIAL SAFETY & FEASIBILITY DATA TO GUIDE AND INFORM THE CLINICAL TRANSLATION OF HISTOTRIPSY AS A NON-INVASIVE LIMB SALVAGE TREATMENT FOR OS.

Posted 6/20/24, 12:00 AM